Showing 1581-1590 of 3043 results for "".
- ADAM Accepting Nominations for Practice Manager of the Yearhttps://practicaldermatology.com/news/adam-accepting-nominations-for-practice-manager-of-the-year/2458363/The Association of Dermatology Administrators and Managers is accepting nominations for its annual Practice Manager of the Year Award. Now in its fourth year, the Practice Manager of the Year Award recognizes the office professional who best demonstrates innovative thinking, ins
- Office Job, Stress And Diet May Increase Risk of Adult Acnehttps://practicaldermatology.com/news/office-job-stress-diet-may-increase-risk-of-adult-acne/2458370/Lifestyle factors -- including stress -- may play a role in adult acne development, a new study suggests. Researchers in Italy compared 248 women diagnosed with adult acne to 270 women without acne. They found that adult acne was associated with a personal history of acne in adolesce
- Two New Studies Suggest BPX-01 Topical Minocycline May Hold Advantageshttps://practicaldermatology.com/news/two-new-studies-suggest-bpx-01-topical-minocycline-may-hold-advantages/2458376/Taken together, two new studies suggest that BioPharmX Corp.’s BPX-01 topical minocycline may have a favorable pharmacokinetic advantage compared with oral minocycline for the treatment of acne vulgaris. The research was at the Skin Disease Edu
- Precision Medicine in Action: Clinical Features May Help ID High Risk Melanoma Patientshttps://practicaldermatology.com/news/precision-medicine-in-action-clinical-featires-may-help-id-high-risk-melanoma-patients/2458379/Zeroing in on an individual’s risk factors for melanoma can help identify high-risk patients who may benefit from increased surveillance, new research suggests. Caroline G. Watts, M.P.H., of the University of Sydney, Australia, and coauthors examined clinical features associated wit
- Can IL-33 Blockade Ease Severe Poison Ivy Itch? Mouse Study Says Maybehttps://practicaldermatology.com/news/can-il-33-blockers-ease-severe-poison-ivy-itch/2458382/Blocking interleukin 33 (IL-33) may put the brakes on the uncontrollable itch caused by poison ivy, poison sumac, poison oak and even mango trees, according to a mouse study conducted by scientists at Duke Health in Durham, NC, and Zhejiang Chinese Medical University in China. The r
- New From Dr. Macrene 37 Actives: High Performance Anti-Aging and Filler Lip Treatmenthttps://practicaldermatology.com/news/new-from-dr-macrene-37-actives-high-performance-anti-aging-and-filler-lip-treatment/2458388/Dr. Macrene 37 Actives is rolling out a new needle-free anti-aging lip filler. 37 Actives High Performance Anti-Aging and Filler Lip Treatment is formulated with more than 20 anti-aging actives including high concentrations of hyaluronic acid and peptides to fight the appearance of wrinkl
- The Election and The Marketshttps://practicaldermatology.com/news/the-election-and-the-markets/2458392/By David Mandell, JD, MBA and Robert Peelman, CFP® This presidential race is seemingly generating more interest, expressions of concern, and questions from clients than past elections. Some clients want to know how the election impacts our investment views and how we might ad
- Aesthetics Industry Veteran Pat Altavilla Joins Suneva Medical As Vice President Of Marketinghttps://practicaldermatology.com/news/aesthetics-industry-veteran-pat-altavilla-joins-suneva-medical-as-vice-president-of-marketing/2458410/Suneva Medical, Inc., appointed Pat Altavilla as vice president of marketing. With more than 30 years of experience in the aesthetics and medical fields, Altavilla will oversee all marketing aspects for the company, further fortifying the brand's strong le
- Beauty Business to Go Green with New Master Class, Institutehttps://practicaldermatology.com/news/beauty-business-to-go-green-with-new-master-class-institute/2458421/The newly formed National Beauty Science Institute (NBSI) aims to promote sustainability, authenticity and green energy in the beauty business. The group will hold its first Master Class in April 2017 to educate students and consumers on the science and sustainability of beauty – a
- Alopecia Areata Breakthrough: Two Studies Suggest JAK inhibitors May Spur Hair Regrowthhttps://practicaldermatology.com/news/alopecia-areata-breakthrough-two-studies-suggest-jak-inhibitors-may-spur-hair-regrowth/2458427/Taken together, two new studies suggest that JAK inhibitors may play a role in treating alopecia areata. Two JAK inhibitors are already approved by the U.S. FDA, XELJANZ® (tofacitinib citrate) for rheumat